Literature DB >> 542586

Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma cortisol.

W J Jeffcoate, J T Silverstone, C R Edwards, G M Besser.   

Abstract

The incidence of psychiatric abnormalities has been assessed in 38 patients with Cushing's syndrome and two with alcohol-induced pseudo-Cushing's syndrome. Twenty-six patients were examined by one of us using a standardized psychiatric interview, and this group included all those with severe to moderate psychiatric disorders. Depression was the commonest symptom: five patients (13%) were markedly or severely depressed, four (10%) were moderately depressed and 13 (32%) were mildly depressed. Four patients exhibited other, non-depressive psychiatric symptoms and only 14 (35%) were judged free from psychiatric abnormality. The first line of treatment was to reduce the circulating cortisol level either by adrenalectomy or by treatment with oral metyrapone; both patients with alcohol-induced pseudo-Cushing's syndrome were treated by alcohol withdrawal. Once the plasma cortisol level was successfully controlled, depressive symptoms were relieved in all five patients with marked or severe depression and in three of the four who were moderately depressed. Mild depressive symptoms were relieved in six of the 13 affected. It is concluded that metyrapone may be of considerable value in the management of the acute psychiatric states which may occur in Cushing's syndrome and these findings are discussed in the light of their possible pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 542586

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  21 in total

1.  Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients.

Authors:  Eleni Daniel; Simon Aylwin; Omar Mustafa; Steve Ball; Atif Munir; Kristien Boelaert; Vasileios Chortis; Daniel J Cuthbertson; Christina Daousi; Surya P Rajeev; Julian Davis; Kelly Cheer; William Drake; Kirun Gunganah; Ashley Grossman; Mark Gurnell; Andrew S Powlson; Niki Karavitaki; Isabel Huguet; Tara Kearney; Kumar Mohit; Karim Meeran; Neil Hill; Aled Rees; Andrew J Lansdown; Peter J Trainer; Anna-Elisabeth H Minder; John Newell-Price
Journal:  J Clin Endocrinol Metab       Date:  2015-09-09       Impact factor: 5.958

Review 2.  [New insights into the pathogenesis and pathophysiology of depression].

Authors:  C Schüle; T C Baghai; R Rupprecht
Journal:  Nervenarzt       Date:  2007-11       Impact factor: 1.214

3.  Corticosterone mediates the synaptic and behavioral effects of chronic stress at rat hippocampal temporoammonic synapses.

Authors:  Mark D Kvarta; Keighly E Bradbrook; Hannah M Dantrassy; Aileen M Bailey; Scott M Thompson
Journal:  J Neurophysiol       Date:  2015-07-15       Impact factor: 2.714

Review 4.  Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment.

Authors:  N Sonino; G A Fava
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  Mania in association with hydrocortisone replacement for Addison's disease.

Authors:  E Ur; T H Turner; T J Goodwin; A Grossman; G M Besser
Journal:  Postgrad Med J       Date:  1992-01       Impact factor: 2.401

Review 6.  Effects of adrenal cortex hormones on limbic structures: some experimental and clinical correlations related to depression.

Authors:  B Dubrovsky
Journal:  J Psychiatry Neurosci       Date:  1993-01       Impact factor: 6.186

7.  Dexamethasone target sites in the central nervous system and their potential relevance to mental illness.

Authors:  M K Birmingham; M Sar; W E Stumpf
Journal:  Cell Mol Neurobiol       Date:  1993-08       Impact factor: 5.046

8.  Effects of adrenocortical steroids on long-term potentiation in the limbic system: basic mechanisms and behavioral consequences.

Authors:  B Dubrovsky; K Gijsbers; D Filipini; M K Birmingham
Journal:  Cell Mol Neurobiol       Date:  1993-08       Impact factor: 5.046

Review 9.  Drug-induced mania.

Authors:  M Peet; S Peters
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

10.  Evaluation of depression, quality of life and body image in patients with Cushing's disease.

Authors:  Nilufer Alcalar; Sedat Ozkan; Pinar Kadioglu; Ozlem Celik; Penbe Cagatay; Baris Kucukyuruk; Nurperi Gazioglu
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.